576 related articles for article (PubMed ID: 19088831)
41. Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.
Habal P; Omran N; Jankovicova K; Krejsek J; Mandak J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):234-41. PubMed ID: 25059234
[TBL] [Abstract][Full Text] [Related]
42. Pleurodesis Using Mistletoe Extract Delivered via a Spray Catheter during Semirigid Pleuroscopy for Managing Symptomatic Malignant Pleural Effusion.
Eom JS; Ahn HY; Mok JH; Lee G; Jo EJ; Kim MH; Lee K; Kim KU; Park HK; Lee MK
Respiration; 2018; 95(3):177-181. PubMed ID: 29131094
[TBL] [Abstract][Full Text] [Related]
43. Talc slurry pleurodesis via chest tube in department of pulmonology--a 24-case study.
Gawron G; Gabryś J; Barczyk A
Pneumonol Alergol Pol; 2013; 81(5):439-47. PubMed ID: 23996883
[TBL] [Abstract][Full Text] [Related]
44. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial.
Mohsen TA; Zeid AA; Meshref M; Tawfeek N; Redmond K; Ananiadou OG; Haj-Yahia S
Eur J Cardiothorac Surg; 2011 Aug; 40(2):282-6. PubMed ID: 20961772
[TBL] [Abstract][Full Text] [Related]
45. [Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].
Charvat JC; Brutsche M; Frey JG; Tschopp JM
Praxis (Bern 1994); 1998 Mar; 87(10):336-40. PubMed ID: 9545840
[TBL] [Abstract][Full Text] [Related]
46. A study of comparison of efficacy and safety of talc and povidone iodine for pleurodesis of malignant pleural effusions.
Das SK; Saha SK; Das A; Halder AK; Banerjee SN; Chakraborty M
J Indian Med Assoc; 2008 Sep; 106(9):589-90, 592. PubMed ID: 19552086
[TBL] [Abstract][Full Text] [Related]
47. Interventions for the management of malignant pleural effusions: a network meta-analysis.
Clive AO; Jones HE; Bhatnagar R; Preston NJ; Maskell N
Cochrane Database Syst Rev; 2016 May; 2016(5):CD010529. PubMed ID: 27155783
[TBL] [Abstract][Full Text] [Related]
48. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses.
Steger V; Mika U; Toomes H; Walker T; Engel C; Kyriss T; Ziemer G; Friedel G
Ann Thorac Surg; 2007 Jun; 83(6):1940-5. PubMed ID: 17532375
[TBL] [Abstract][Full Text] [Related]
49. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions.
Hartman DL; Gaither JM; Kesler KA; Mylet DM; Brown JW; Mathur PN
J Thorac Cardiovasc Surg; 1993 Apr; 105(4):743-7; discussion 747-8. PubMed ID: 7682268
[TBL] [Abstract][Full Text] [Related]
50. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions.
Ong KC; Indumathi V; Raghuram J; Ong YY
Respirology; 2000 Jun; 5(2):99-103. PubMed ID: 10894097
[TBL] [Abstract][Full Text] [Related]
51. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion.
Yim AP; Chan AT; Lee TW; Wan IY; Ho JK
Ann Thorac Surg; 1996 Dec; 62(6):1655-8. PubMed ID: 8957368
[TBL] [Abstract][Full Text] [Related]
52. Thoracoscopic collagen pleurodesis in the treatment of malignant pleural effusions.
Akopov AL; Egorov VI; Varlamov VV; Levashev YN; Artioukh DY
Eur J Cardiothorac Surg; 2005 Nov; 28(5):750-3. PubMed ID: 16198593
[TBL] [Abstract][Full Text] [Related]
53. [Effective treatment of malignant pleural effusion: Thoracoscopic talcum pleurodesis and pleuro-peritoneal shunt].
Böhle AS; Kurdow R; Dohrmann P; Henne-Bruns D
Dtsch Med Wochenschr; 1999 Mar; 124(12):341-5. PubMed ID: 10214366
[TBL] [Abstract][Full Text] [Related]
54. Thoracoscopic talc poudrage for malignant effusions: should it be the procedure of choice?
Yim AP; Izzat MB
Chest; 1997 Oct; 112(4):1148. PubMed ID: 9377939
[No Abstract] [Full Text] [Related]
55. Comparing approaches to the management of malignant pleural effusions.
Porcel JM; Lui MM; Lerner AD; Davies HE; Feller-Kopman D; Lee YC
Expert Rev Respir Med; 2017 Apr; 11(4):273-284. PubMed ID: 28271728
[TBL] [Abstract][Full Text] [Related]
56. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
Lumachi F; Mazza F; Ermani M; Chiara GB; Basso SM
Anticancer Res; 2012 Nov; 32(11):5071-4. PubMed ID: 23155281
[TBL] [Abstract][Full Text] [Related]
57. Tumor type influences the effectiveness of pleurodesis in malignant effusions.
Bielsa S; Hernández P; Rodriguez-Panadero F; Taberner T; Salud A; Porcel JM
Lung; 2011 Apr; 189(2):151-5. PubMed ID: 21331598
[TBL] [Abstract][Full Text] [Related]
58. Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion.
Ibrahim IM; Dokhan AL; El-Sessy AA; Eltaweel MF
J Cardiothorac Surg; 2015 May; 10():64. PubMed ID: 25947235
[TBL] [Abstract][Full Text] [Related]
59. Thoracoscopic talc pleurodesis for the treatment of spontaneous pneumothorax.
Pletinckx P; Muysoms F; De Decker C; Daeter E; Claeys D
Acta Chir Belg; 2005; 105(5):504-7. PubMed ID: 16315834
[TBL] [Abstract][Full Text] [Related]
60. Predictors of talc pleurodesis outcome in patients with malignant pleural effusions.
Yildirim H; Metintas M; Ak G; Metintas S; Erginel S
Lung Cancer; 2008 Oct; 62(1):139-44. PubMed ID: 18403045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
